Parse Biosciences, a Seattle, WA-based provider of scalable single cell sequencing solutions, raised $50M in financing from a Series C equity and the closing of a debt facility.
Soleus Capital led the Series C equity financing, with participation from new and current investors including Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, and Saras Capital. Horizon Technology Finance Corporation (Nasdaq: HRZN) provided the debt facility. It brought the company’s total funding to over $100M.
The company intends to use the funds to drive expansion of its product portfolio and commercial reach.
Led by CEO Alex Rosenberg, Ph.D, Parse Biosciences is a life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with scale and ease, its approach is enabling discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Parse’s single cell portfolio, which includes Evercode™ Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect, and data analysis solutions, is now available in a growing number of key international markets, including Australia, Europe, India, Israel, New Zealand, Singapore, and South Korea.
Founded based on technology invented at the University of Washington, Parse is used by over 1,000 labs across the world.
FinSMEs
14/12/2023